{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:31:37Z","timestamp":1781033497022,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In idiopathic intracranial hypertension (IIH), certain MRI features are promising diagnostic markers, but whether these have prognostic value is currently unknown.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included patients from the Vienna-Idiopathic-Intracranial-Hypertension (VIIH) database with IIH according to Friedman criteria and cranial MRI performed at diagnosis. Presence of empty sella (ES), perioptic subarachnoid space distension (POSD) with or without optic nerve tortuosity (ONT), posterior globe flattening (PGF) and transverse sinus stenosis (TSS) was assessed and multivariable regression models regarding visual outcome (persistent visual impairment\/visual worsening) and headache outcome (headache improvement\/freedom of headache) were fitted.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 84 IIH patients (88.1% female, mean age 33.5 years, median body mass index 33.7). At baseline, visual impairment was present in 70.2% and headache in 84.5% (54.8% chronic). Persistent visual impairment occurred in 58.3%, visual worsening in 13.1%, headache improvement was achieved in 83.8%, freedom of headache in 26.2%.<\/jats:p>\n                <jats:p>At least one MRI feature was found in 78.6% and 60.0% had \u22653 features with POSD most frequent (64.3%) followed by TSS (60.0%), ONT (46.4%), ES (44.0%) and PGF (23.8%).<\/jats:p>\n                <jats:p>In multivariable models, there was no association of any single MRI feature or their number with visual impairment, visual worsening, headache improvement or freedom.<\/jats:p>\n                <jats:p>Visual impairment at baseline predicted persistent visual impairment (odds ratio 6.3, p&lt;0.001), but not visual worsening. Chronic headache at baseline was significantly associated with lower likelihood of headache freedom (odds ratio 0.48, p=0.013), but not with headache improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MRI features of IIH are neither prognostic of visual nor headache outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01641-x","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:02:59Z","timestamp":1690567379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["MRI features of idiopathic intracranial hypertension are not prognostic of visual and headache outcome"],"prefix":"10.1186","volume":"24","author":[{"given":"Gabriel","family":"Bsteh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Marik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Krajnc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Macher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Pruckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"W\u00f6ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Pemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"1641_CR1","doi-asserted-by":"crossref","unstructured":"Radhakrishnan K, Ahlskog JE, Cross SA et al (1993) Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Descriptive Epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol-chicago 50(1):78\u201380","DOI":"10.1001\/archneur.1993.00540010072020"},{"key":"1641_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2017.01.006","volume":"124","author":"KP Kilgore","year":"2017","unstructured":"Kilgore KP, Lee MS, Leavitt JA et al (2017) Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology 124:697\u2013700","journal-title":"Ophthalmology"},{"key":"1641_CR3","doi-asserted-by":"publisher","unstructured":"Raoof N, Hoffmann J (2021) Diagnosis and treatment of idiopathic intracranial hypertension. Cephalalgia 18(10):1266\u20138. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03372.x. Epub 2011 Mar 22","DOI":"10.1111\/j.1468-1331.2011.03372.x"},{"key":"1641_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s42399-021-00814-6","volume":"3","author":"MG Peng","year":"2021","unstructured":"Peng MG, Gokoffski KK (2021) Updates on recent developments in idiopathic intracranial hypertension. SN Compr Clin Medicine 3:1031\u20131041","journal-title":"SN Compr Clin Medicine"},{"key":"1641_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159\u20131165","journal-title":"Neurology"},{"key":"1641_CR6","doi-asserted-by":"publisher","unstructured":"Barkatullah AF, Leishangthem L, Moss HE (2021) MRI findings as markers of idiopathic intracranial hypertension. Curr Opin Neurol 34(1):75\u201383. https:\/\/doi.org\/10.1097\/WCO.0000000000000885","DOI":"10.1097\/WCO.0000000000000885"},{"key":"1641_CR7","doi-asserted-by":"publisher","unstructured":"Mallery RM, Rehmani OF, Woo JH et al (2019) Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema. J Neuro-ophthalmol 39(3):299\u2013307. https:\/\/doi.org\/10.1097\/WNO.0000000000000767","DOI":"10.1097\/WNO.0000000000000767"},{"key":"1641_CR8","doi-asserted-by":"publisher","unstructured":"Bsteh G, Marik W, Macher S et al (2023) Impact of rater experience and referral question on detecting MRI features of idiopathic intracranial hypertension. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15986. Online ahead of print","DOI":"10.1111\/ene.15986"},{"key":"1641_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2214\/AJR.12.9638","volume":"201","author":"AM Saindane","year":"2013","unstructured":"Saindane AM, Bruce BB, Riggeal BD et al (2013) Association of MRI findings and visual outcome in idiopathic intracranial hypertension. Ajr Am J Roentgenol 201:412\u2013418","journal-title":"Ajr Am J Roentgenol"},{"key":"1641_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clineuro.2017.05.009","volume":"159","author":"A Agarwal","year":"2017","unstructured":"Agarwal A, Vibha D, Prasad K et al (2017) Predictors of poor visual outcome in patients with idiopathic intracranial hypertension (IIH): an ambispective cohort study. Clin Neurol Neurosur 159:13\u201318","journal-title":"Clin Neurol Neurosur"},{"key":"1641_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/19714009211000623","volume":"34","author":"N Prabhat","year":"2021","unstructured":"Prabhat N, Chandel S, Takkar DA et al (2021) Sensitivity and specificity of neuroimaging signs in patients with idiopathic intracranial hypertension. Neuroradiol J 34:421\u2013427","journal-title":"Neuroradiol J"},{"key":"1641_CR12","doi-asserted-by":"publisher","unstructured":"Chagot C, Blonski M, Machu J-L et al (2017) Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary Management. J Obes\u00a05348928. https:\/\/doi.org\/10.1155\/2017\/5348928. Epub 2017 Aug 13.","DOI":"10.1155\/2017\/5348928"},{"key":"1641_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41433-021-01651-6","volume":"36","author":"A Eshtiaghi","year":"2022","unstructured":"Eshtiaghi A, Zaslavsky K, Nicholson P et al (2022) Extent of transverse sinus stenosis does not predict visual outcomes in idiopathic intracranial hypertension. Eye 36:1390\u20131395","journal-title":"Eye"},{"key":"1641_CR14","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1638134\/v1","author":"P Pruckner","year":"2023","unstructured":"Pruckner P, Mitsch C, Macher S et al (2023) The Vienna Idiopathic Intracranial Hypertension (VIIH) database \u2013 an austrian registry. Wien Klin Wochenschr (2023) in press\u00a0https:\/\/doi.org\/10.21203\/rs.3.rs-1638134\/v1","journal-title":"Wi Kli Wo"},{"key":"1641_CR15","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS)\u00a0 The International Classification of Headache Disorders, 3rd edition\u00a0(2018) Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1641_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/1522-2586(200012)12:6<808::AID-JMRI3>3.0.CO;2-N","volume":"12","author":"WTC Yuh","year":"2000","unstructured":"Yuh WTC, Zhu M, Taoka T et al (2000) MR imaging of pituitary morphology in idiopathic intracranial hypertension. J Magn Reson Imaging 12:808\u2013813","journal-title":"J Magn Reson Imaging"},{"key":"1641_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejrad.2019.04.023","volume":"116","author":"RM Kwee","year":"2019","unstructured":"Kwee RM, Kwee TC (2019) Systematic review and meta-analysis of MRI signs for diagnosis of idiopathic intracranial hypertension. Eur J Radiol 116:106\u2013115","journal-title":"Eur J Radiol"},{"key":"1641_CR18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/01.WNL.0000066683.34093.E2","volume":"60","author":"RI Farb","year":"2003","unstructured":"Farb RI, Vanek I, Scott JN et al (2003) Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 60:1418\u20131424","journal-title":"Neurology"},{"key":"1641_CR19","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-1100","volume":"44","author":"DA Rosser","year":"2003","unstructured":"Rosser DA, Cousens SN, Murdoch IE et al (2003) How sensitive to clinical change are ETDRS logMAR Visual acuity measurements? Invest Ophth Vis Sci 44:3278\u20133281","journal-title":"Invest Ophth Vis Sci"},{"key":"1641_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. Statist Med 21:2409\u20132419","journal-title":"Statist Med"},{"key":"1641_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-statistics-041715-033413","volume":"3","author":"G Claeskens","year":"2016","unstructured":"Claeskens G (2016) Statistical model choice. Annu Rev Stat Appl 3:233\u2013256","journal-title":"Annu Rev Stat Appl"},{"key":"1641_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB (1984) Reducing Bias in Observational Studies using subclassification on the Propensity score. J Am Stat Assoc 79:516\u2013524","journal-title":"J Am Stat Assoc"},{"key":"1641_CR23","doi-asserted-by":"publisher","unstructured":"Council National Research. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press, US (2010) (), Epub ahead of print 2010.\u00a0\u00a0https:\/\/doi.org\/10.17226\/12955","DOI":"10.17226\/12955"},{"key":"1641_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2014.133","volume":"71","author":"M Wall","year":"2014","unstructured":"Wall M, Kupersmith MJ, Kieburtz KD et al (2014) The idiopathic intracranial hypertension treatment trial: Clinical Profile at Baseline. Jama Neurol 71:693\u2013701","journal-title":"Jama Neurol"},{"key":"1641_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1167\/iovs.15-18626","volume":"57","author":"M Wall","year":"2016","unstructured":"Wall M, Johnson CA, Cello KE et al (2016) Visual field outcomes for the idiopathic intracranial hypertension treatment trial (IIHTT)visual field outcomes. Invest Ophth Vis Sci 57:805\u2013812","journal-title":"Invest Ophth Vis Sci"},{"key":"1641_CR26","doi-asserted-by":"publisher","first-page":"105378","DOI":"10.1016\/j.clineuro.2019.105378","volume":"183","author":"G Tata","year":"2019","unstructured":"Tata G, Kisabay A, Gokcay F et al (2019) Idiopathic intracranial hypertension: are there predictors for visual outcome or recurrences? Clin Neurol Neurosur 183:105378","journal-title":"Clin Neurol Neurosur"},{"key":"1641_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.58.10.1551","volume":"58","author":"DI Friedman","year":"2002","unstructured":"Friedman DI, Rausch EA (2002) Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 58:1551\u20131553","journal-title":"Neurology"},{"key":"1641_CR28","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/ene.12512","volume":"21","author":"HM Yri","year":"2014","unstructured":"Yri HM, R\u00f6nnb\u00e4ck C, Wegener M et al (2014) The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow\u2010up study. Eur J Neurol 21:1458\u20131464","journal-title":"Eur J Neurol"},{"key":"1641_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/WNO.0000000000000777","volume":"39","author":"DI Friedman","year":"2019","unstructured":"Friedman DI (2019) Headaches in idiopathic intracranial hypertension. J Neuro-ophthalmol 39:82\u201393","journal-title":"J Neuro-ophthalmol"},{"key":"1641_CR30","doi-asserted-by":"publisher","unstructured":"Simone RD, Sansone M, Bonavita V (2020) Headache in idiopathic intracranial hypertension. A CGRP-dependent head pain? Neurol Sci 41(Suppl 2):417\u201321. https:\/\/doi.org\/10.1007\/s10072-020-04641-w","DOI":"10.1007\/s10072-020-04641-w"},{"key":"1641_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-015-0521-9","volume":"16","author":"Y Mulla","year":"2015","unstructured":"Mulla Y, Markey KA, Woolley RL et al (2015) Headache determines quality of life in idiopathic intracranial hypertension. J Headache Pain 16:45","journal-title":"J Headache Pain"},{"key":"1641_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-021-01283-x","volume":"22","author":"M Witry","year":"2021","unstructured":"Witry M, Kindler C, Weller J et al (2021) The patients\u2019 perspective on the burden of idiopathic intracranial hypertension. J Headache Pain 22:67","journal-title":"J Headache Pain"},{"key":"1641_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3171\/jns.2004.101.4.0627","volume":"101","author":"MJ Mcgirt","year":"2004","unstructured":"Mcgirt MJ, Woodworth G, Thomas G et al (2004) Cerebrospinal fluid shunt placement for pseudotumor cerebri\u2014associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg 101:627\u2013632","journal-title":"J Neurosurg"},{"key":"1641_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s10194-020-01182-7","volume":"21","author":"A Yiangou","year":"2020","unstructured":"Yiangou A, Mitchell JL, Vijay V et al (2020) Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain 21:116","journal-title":"J Headache Pain"},{"key":"1641_CR35","doi-asserted-by":"publisher","unstructured":"Bsteh G, Macher S, Krajnc N et al Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes. Headache J Head Face Pain 63(5):601\u201310. https:\/\/doi.org\/10.1111\/head.14478. Epub 2023 Feb 8","DOI":"10.1111\/head.14478"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01641-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:03:03Z","timestamp":1690567383000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01641-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Medical University Vienna (approval number: 2216\/2020). As this is a retrospective documentation of clinical routine data, the need for written informed consent from study participants was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GB: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene\/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene\/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene\/BMS and Novartis. WM: declares no conflict of interest relevant to this study. SM: declares no conflict of interest relevant to this study. VS: declares no conflict of interest relevant to this study\/ NK: has participated in meetings sponsored by, received speaker honoraria or travel funding from BMS\/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). PP: declares no conflict of interest relevant to this study. CM: declares no conflict of interest relevant to this study. KN: declares no conflict of interest relevant to this study. CW: has received honoraria consultancy\/speaking from Apomedica, Curelator, Eli Lilly, Gr\u00fcnenthal, Hermes, Novartis, Pfizer, Ratiopharm\/Teva, and Stada. BP: declares no conflict of interest relevant to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}